Our aim was to clarify the optimum pre-ablative thyroid-stimulating hormone (TSH) level for
initial radioiodine remnant ablation (RRA) in patients with differentiated thyroid carcinoma …

Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

Purpose To determine whether thyroid-stimulating hormone level≥ 30 mU/L is necessary
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …

Purpose The aim of this study was to evaluate the efficacy of post-operative radioiodine
ablation with 1,850 MBq after recombinant human thyrotropin (rhTSH) administration in …

Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …

Aim We aim to assess the effects of recombinant human thyrotropin (rhTSH) versus thyroid
hormone withdrawal (THW), and rhTSH-aided low doses (1.11 GBq and 1.85 GBq) versus …

We evaluated the efficacy of recombinant human thyroid-stimulating hormone (rhTSH)
versus thyroid hormone withdrawal (THW) prior to radioiodine remnant ablation (RRA) in …

The effects of low-activity versus high-activity radioiodine regimens in thyroid remnant
ablation for patients with differentiated thyroid carcinoma (DTC) under recombinant human …

Context: There is uncertainty over the dose of 131I required for thyroid remnant ablation.
Most previous studies have been inadequately powered to establish the best fixed dose of …

Results Sixty-four patients had papillary thyroid carcinoma, whereas 45 patients had
follicular carcinoma. An excellent response was observed in 66.7% of patients with TSH …